What changed for Friedreich Ataxia
A plain English summary of what recently moved in the public data Voxsanity tracks for Friedreich Ataxia. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 16 to 15 (-1)
- Trials on record 100 to 99 (-1)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Friedreich Ataxia yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Friedreich Ataxia that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04577352 · results posted 8 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04577352) enrolled 146 people with Friedreich's ataxia — 73 in the vatiquinone group and 73 in the placebo group. The main 72-week blinded phase was completed by 63 people in the vatiquinone group and 65 in the placebo group. The trial was primarily measuring changes in a neurological test called the mFARS score, which rates things like balance, limb coordination, and speech on a scale of 0 (normal) to 93 (greatest impairment) — so a smaller increase over time means less worsening. There was also an additional 24-week open...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04192136 · results posted 11 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04192136) enrolled 75 people in total across five groups. Four groups — comprising 66 participants — were randomly assigned to one of four combinations: a supplement called Nicotinamide Riboside (NR) alone, a placebo (inactive treatment) alone, exercise plus NR, or exercise plus placebo. A fifth group of 9 people were not randomised and did not complete the study. All 66 randomised participants finished the trial. The trial was measuring two main things: how well participants' hearts and lungs could use oxygen during exerc...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03418740 · results posted 16 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 108 children with Friedreich's Ataxia (FA), a rare inherited condition that affects the nervous system and movement. Of those, 89 were included in the main analysis and 85 completed the study. The trial was not testing a treatment — rather, it was an observational study tracking how several measures of movement, balance, and daily functioning changed over three years in this group of children. Measurements were taken at the start of the study and then at one, two, and three years. The reported data shows that the pri...
-
NCT04817111 · results posted 17 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04817111) enrolled 7 adults who all received an experimental supplement called MIB-626. All 7 participants completed the study. The trial was a single-group, open-label study — meaning everyone received the same treatment and both participants and researchers knew what was being given. The main thing researchers were looking at was how many participants experienced unwanted side effects (called "adverse events") while taking MIB-626, graded using a standard medical rating scale. They also took a range of measurements befor...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02255435 · results posted 29 November 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02255435) involved people with Friedreich's ataxia, a rare condition affecting movement and coordination. The trial was run in two parts. Part 1 enrolled 69 participants across seven dose groups of a medicine called omaveloxolone (ranging from 2.5 mg up to 300 mg) plus a placebo group of 17 people, to explore different doses over 12 weeks. Part 2 enrolled 103 participants — 52 on placebo and 51 on a 150 mg dose of omaveloxolone — over 48 weeks. Part 1 looked mainly at how hard participants could work on a stationary exerci...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04102501 · results posted 27 May 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04102501) involved 65 participants in total — 33 received a treatment called RT001 and 32 received a placebo (a dummy treatment with no active ingredient). The trial ran for 11 months and was measuring two things: how much oxygen the body can use at maximum effort during a supervised exercise test (known as a cardiopulmonary exercise test), and how far participants could walk in one minute. The reported data shows that for the main measure — the change in maximum oxygen use from the start of the trial to 11 months — the R...
-
NCT02660112 · results posted 5 December 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02660112) involved 10 participants, all of whom completed the study with no drop-outs. The trial was looking at a compound called (+)-Epicatechin and measuring two main things in people with Friedreich's Ataxia: changes in a disability rating scale called the FARS (Friedreich Ataxia Rating Scale), and changes in heart muscle thickness as seen on a cardiac MRI scan. The FARS score combines several tests — including walking speed, hand coordination, speech speed, and vision — into a single number ranging from 0 to 159, where...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03120013 · results posted 28 June 2019
According to the results reported on ClinicalTrials.gov, this trial involved 21 people in total (10 in one group, 11 in the other), all of whom had ataxia — a condition affecting balance and coordination. It was a "crossover" trial, meaning everyone received both the real treatment and a sham (dummy) version at different times, with a six-month rest period in between. The treatment being tested was tDCS (transcranial direct current stimulation), a technique that passes a very mild electrical current through the scalp. The trial measured changes in participants' ataxia symptoms using several ra...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02593773 · results posted 18 May 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT02593773) enrolled 86 people, all of whom received the study drug Interferon γ-1b. The trial was an extension study, meaning participants had previously taken part in an earlier related trial. Of the 86 who started, 51 completed the study and 35 did not finish. The trial was measuring a range of things, including any unwanted medical events that occurred during treatment, whether the body produced antibodies (proteins) against the drug, and changes in scores on several rating scales that assess movement, coordination, and...
-
NCT02797080 · results posted 1 May 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT02797080) involved 38 participants who all received a treatment called Interferon γ-1b. Of those 38 people, 36 completed the study and 2 did not finish. The trial was measuring how participants responded to the treatment in terms of unwanted medical events — specifically, it tracked what are called "treatment-emergent adverse events" (unexpected or unwanted health changes that occurred after starting the medication), "serious adverse events" (more severe health events such as hospitalisation or life-threatening situations)...
-
NCT00993967 · results posted 5 March 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 200 people, all of whom received the study drug, idebenone. The trial was measuring two main things: first, how often and what kinds of unwanted effects (called adverse events) occurred; and second, whether there were any changes in a standard rating scale used to assess a type of movement disorder called ataxia — the International Cooperative Ataxia Rating Scale, or ICARS. The ICARS looks at things like balance, walking, coordination of the arms and legs, speech, and eye movements, and gives a total score from 0 (lea...
-
NCT01716221 · results posted 19 September 2016
According to the results reported on ClinicalTrials.gov, this trial enrolled just one participant, who completed the full study. The trial was looking at the effects of two medicines — bupropion and citalopram — on a condition called Friedreich's ataxia, a disease that affects movement and coordination. The participant went through several different treatment combinations over approximately 20 weeks, and their symptoms were tracked using two established rating scales: the International Cooperative Ataxia Rating Scale (ICARS, scored 0–100, where higher means more severe symptoms) and the Friedr...
-
NCT00905268 · results posted 27 June 2016
According to the results reported on ClinicalTrials.gov, this trial (NCT00905268) involved 232 people with Friedreich's ataxia — a condition affecting coordination and movement. Participants were divided into four groups: three groups received different doses of a medicine called idebenone (57, 57, and 59 people respectively), and one group of 59 people received a placebo (a dummy treatment with no active ingredient). The trial ran for 52 weeks and was primarily measuring changes in a coordination rating scale called ICARS, which runs from 0 to 100, where higher scores mean greater difficulty...
-
NCT01303406 · results posted 9 March 2016
According to the results reported on ClinicalTrials.gov, this trial involved 29 people in total — 13 received a placebo (a dummy treatment with no active ingredient) and 16 received idebenone, a medicine being investigated for Friedreich's ataxia (FRDA), a rare inherited condition affecting movement and coordination. All 13 people in the placebo group and 15 of the 16 in the idebenone group completed the trial (one person in the idebenone group did not finish). The trial was primarily measuring whether participants could correctly guess which treatment they had received — placebo or idebenone...
-
NCT01965327 · results posted 30 April 2015
According to the results reported on ClinicalTrials.gov, this trial (NCT01965327) enrolled 12 people with Friedreich's ataxia, a rare inherited condition affecting the nervous system. All 12 participants received a treatment called Interferon Gamma-1b (also known as ACTIMMUNE). Ten participants completed the trial, while two did not finish. The trial was primarily measuring whether the treatment changed levels of a protein called frataxin in the blood — frataxin is produced at lower-than-normal levels in people with Friedreich's ataxia. A secondary goal was to track any change in participants'...
-
NCT00824512 · results posted 21 May 2013
According to the results reported on ClinicalTrials.gov, this trial enrolled 22 people in total — 11 in each group. One group took a 120 mg dose of a ginkgo biloba extract called EGb 761®, and the other group took a placebo (a dummy treatment). All 22 participants completed the trial. The study was measuring how well muscles recover after exercise, looking specifically at how quickly muscles restore their energy, how much blood flows to the muscle after exercise, how fast oxygen returns to the muscle, and the size of the muscle — all measured using specialised imaging and scanning techniques....
-
NCT00537680 · results posted 29 December 2011
According to the results reported on ClinicalTrials.gov, this trial looked at two different doses of a medicine called idebenone — a "mid dose" and a "high dose" — compared to a dummy treatment (placebo) in people with Friedreich's ataxia, a condition affecting movement and coordination. A total of 70 people started the trial (22 in the mid-dose group, 24 in the high-dose group, and 24 in the placebo group), and 68 completed it. The trial ran for 24 weeks and used several rating scales to measure changes in movement, coordination, daily activities, and heart structure. The reported data shows...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00697073 · results posted 4 August 2011
According to the results reported on ClinicalTrials.gov, this trial involved 68 people with Friedreich's ataxia who received a high dose of a medicine called idebenone. Of those 68 participants, 59 completed the study and 9 did not finish. The trial was measuring changes in two rating scales commonly used to assess Friedreich's ataxia — the ICARS (International Cooperative Ataxia Rating Scale, scored from 0 to 100, where a lower score means less disability) and the FARS (Friedreich's Ataxia Rating Scale, scored from 0 to 159, where a lower score also means less disability). The reported data...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a moderate amount of public research investment is currently directed toward Friedreich Ataxia, and encouragingly, that investment has been rising over time. For patients, a growing funding trend generally means that more scientific questions are being asked and more research teams are being supported to find answers. While funding alone does not guarantee breakthrou...
See the full Friedreich Ataxia page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.